Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
206.1 USD | +1.82% | +6.44% | -20.05% |
Apr. 25 | Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA | CI |
Apr. 25 | Goldman Sachs Adjusts Biogen Price Target to $340 From $393 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.05% | 29.48B | |
-4.66% | 87.53B | |
+2.63% | 40.42B | |
+57.86% | 25.43B | |
-18.11% | 11.49B | |
-44.02% | 11.3B | |
-15.61% | 11.1B | |
+4.34% | 8.75B | |
-8.42% | 7.99B | |
+0.68% | 7.67B |
- Stock Market
- Equities
- BIIB Stock
- News Biogen Inc.
- RBC Cuts Price Target on Biogen to $310 From $321, Maintains Outperform Rating